Action Intelgenx Technologies - IGX

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

0,24

Prix Achat

0,05

Prix Vente

0,15

Volume échangé

0,00 Fourchette du Jour 0,00

0,185 Plage de 52 semaines 0,26

Clôture Veille

0,24

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process

MONTREAL, July 19, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “Company” or “IntelGenx”) (OTC:...

IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

MONTREAL, July 03, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “Company” or “IntelGenx” a subsidiary of...

IntelGenx Announces Initiation of the Sale and Investment Solicitation Process

MONTREAL, June 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “Company” or “IntelGenx” a subsidiary of...

IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process

MONTREAL, May 28, 2024 (GLOBE NEWSWIRE) -- As previously announced on May 17, 2024, IntelGenx Technologies...

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

MONTREAL, May 17, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “Company” or “IntelGenx”...

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

MONTREAL, May 17, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “Company” or “IntelGenx”...

IntelGenx Announces Voting Results on Election of Directors

SAINT LAURENT, Quebec, May 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT...

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial

SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the...

IntelGenx Updates Status of Buprenorphine Buccal Film ANDA

SAINT LAURENT, Quebec, April 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the...

IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results

SAINT LAURENT, Quebec, March 21, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0.24	0.24	0.24	0	0	CS
4	0	0	0.24	0.24	0.24	0	0	CS
12	0	0	0.24	0.24	0.24	0	0	CS
26	0	0	0.24	0.24	0.24	0	0	CS
52	0.01	4.34782608696	0.23	0.26	0.185	1993	0.2180176	CS
156	-0.08	-25	0.32	0.485	0.135	16996	0.23141045	CS
260	-0.34	-58.6206896552	0.58	0.79	0.135	20735	0.34633097	CS

IGX - Frequently Asked Questions (FAQ)

What is the current Intelgenx Technologies share price?

The current share price of Intelgenx Technologies is $ 0,24

What is the 1 year trading range for Intelgenx Technologies share price?

Intelgenx Technologies has traded in the range of $ 0,185 to $ 0,26 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
PNC.BPostmedia Network Canada Corp	$ 1,10 (37,50%)	11,2k
PNC.APostmedia Network Canada Corp	$ 1,07 (25,88%)	3,4k
FLNTFlint Corporation	$ 0,025 (25,00%)	245,17k
APLIAppili Therapeutics Inc	$ 0,03 (20,00%)	185k
SLT.USaltire Capital Ltd	US$ 8,36 (19,43%)	1,1k
VRTSVertiqal Studios Corporation	$ 0,015 (-25,00%)	60k
GMTNGold Mountain Mining Corp	$ 0,015 (-25,00%)	1,07k
THNCThinkific Labs Inc	$ 2,30 (-19,30%)	19,12k
PPRPrairie Provident Resources Inc	$ 0,03 (-14,29%)	82k
LNLoncor Gold Inc	$ 0,60 (-14,29%)	336,22k
CNQCanadian Natural Resources Ltd	$ 39,89 (2,10%)	19,86M
TDToronto Dominion Bank	$ 83,99 (0,23%)	12,16M
CVECenovus Energy Inc	$ 16,75 (3,65%)	8,12M
ENBEnbridge Inc	$ 62,81 (1,45%)	5,23M
WCPWhitecap Resources Inc	$ 8,20 (2,50%)	4,68M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Intelgenx Technologies Corp (IGX)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

IGX Dernières nouvelles

IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process

IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

IntelGenx Announces Initiation of the Sale and Investment Solicitation Process

IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

IntelGenx Announces Voting Results on Election of Directors

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial

IntelGenx Updates Status of Buprenorphine Buccal Film ANDA

IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results

IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process

IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

IntelGenx Announces Initiation of the Sale and Investment Solicitation Process

IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

IntelGenx Announces Voting Results on Election of Directors

IGX - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Intelgenx Technologies Corp (IGX) Cours

Intelgenx Technologies Corp (IGX)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

IGX Dernières nouvelles

IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process

IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

IntelGenx Announces Initiation of the Sale and Investment Solicitation Process

IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

IntelGenx Announces Voting Results on Election of Directors

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial

IntelGenx Updates Status of Buprenorphine Buccal Film ANDA

IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results

IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process

IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

IntelGenx Announces Initiation of the Sale and Investment Solicitation Process

IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives

IntelGenx Announces Voting Results on Election of Directors

IGX - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités